CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 175 enrolled
Drug / intervention
Buspirone +1 moredrug
Likely dose
Buspirone 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00875836
NCT00875836Phase 4Completed
CompareCT.gov

Buspirone Treatment for Marijuana Dependence

Medical University of South Carolina·interventional·Posted Apr 3, 2009·Updated Aug 10, 2016

In Brief

A Phase 4 clinical trial evaluating Buspirone and Placebo for Marijuana Dependence. Completed, enrolled 175 participants across 1 site.

Detailed Summary

Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of buspirone for reducing marijuana use in marijuana-dependent adults. A contingency management (CM) intervention and motivational enhancement therapy (MET) will be incorporated to encourage study engagement and retention. It is hypothesized that buspirone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarijuana Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 3, 2009
Enrollment StartSep 1, 2009
Primary CompletionJun 1, 2014
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 17.2 years ago

Interventions

Buspironedrug

Flexible dose, up to 60 mg daily

Placebodrug

Flexible dose, up to 60 mg daily